BCoR-L1 variation and breast cancer

[1]  A. Spurdle,et al.  A Novel Corepressor, BCoR-L1, Represses Transcription through an Interaction with CtBP* , 2007, Journal of Biological Chemistry.

[2]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[3]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[4]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[5]  John L Hopper,et al.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.

[6]  A. Whittemore,et al.  The CHEK2*1100delC Allelic Variant and Risk of Breast Cancer: Screening Results from the Breast Cancer Family Registry , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  A. Lindblom,et al.  High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer , 2005, Journal of Medical Genetics.

[8]  David L. Steffen,et al.  The DNA sequence of the human X chromosome , 2005, Nature.

[9]  H. Willard,et al.  X-inactivation profile reveals extensive variability in X-linked gene expression in females , 2005, Nature.

[10]  D. Coradini,et al.  Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. , 2005, Cancer research.

[11]  Joanna H Shih,et al.  Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways , 2004, Oncogene.

[12]  Michael Lietz,et al.  How mammalian transcriptional repressors work. , 2004, European journal of biochemistry.

[13]  Michael R. Green,et al.  When enough is enough: genetic diseases associated with transcriptional derepression. , 2004, Current opinion in genetics & development.

[14]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[15]  H. Kawai,et al.  Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α , 2003, International journal of cancer.

[16]  Circe W. Tsui,et al.  Single nucleotide polymorphisms (SNPs) that map to gaps in the human SNP map. , 2003, Nucleic acids research.

[17]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[18]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[19]  E. Rosen,et al.  BRCA1 gene in breast cancer , 2003, Journal of cellular physiology.

[20]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[21]  R. Spielman,et al.  Natural variation in human gene expression assessed in lymphoblastoid cells , 2003, Nature Genetics.

[22]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[23]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[24]  M. Rosenfeld,et al.  Biological roles and mechanistic actions of co-repressor complexes. , 2002, Journal of cell science.

[25]  J. Sambrook,et al.  Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  A. Børresen-Dale,et al.  High frequency of skewed X inactivation in young breast cancer patients , 2002, Journal of medical genetics.

[28]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[29]  R. Gibbs,et al.  PipMaker--a web server for aligning two genomic DNA sequences. , 2000, Genome research.

[30]  M. O’Donovan,et al.  Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. , 1999, Clinical chemistry.

[31]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[32]  A. Sood,et al.  Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. , 1999, Journal of the National Cancer Institute.

[33]  S. Juhng,et al.  Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas. , 1998, Journal of Korean medical science.

[34]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[35]  Hanlee P. Ji,et al.  Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. , 1997, American journal of human genetics.

[36]  A. Berchuck,et al.  Loss of heterozygosity at chromosome segment Xq25‐26.1 in advanced human ovarian carcinomas , 1997, Genes, chromosomes & cancer.

[37]  W. J. Brammar,et al.  Loss of heterozygosity on the X chromosome in human breast cancer , 1995, Genes, chromosomes & cancer.

[38]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[39]  C. Marshall,et al.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. , 1991, Cancer research.

[40]  J. Dry,et al.  Two identical active X chromosomes in human mammary carcinoma cells. , 1990, Cancer genetics and cytogenetics.

[41]  V. M. Kimel,et al.  Clinical‐cytological correlations of mammary carcinoma based upon sex‐chromatin counts A Preliminary Study , 1957, Cancer.

[42]  T. Hudson,et al.  Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. , 2007, International journal of oncology.

[43]  C. Haldar,et al.  Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. , 2006, Oncology reports.

[44]  M. Cummings,et al.  Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro , 2004, Breast Cancer Research and Treatment.

[45]  Toshimichi Ikemura,et al.  Codon usage tabulated from international DNA sequence databases: status for the year 2000 , 2000, Nucleic Acids Res..

[46]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[47]  R. Amann,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2022 .